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INTRODUCTION
The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable patients to access therapies that are not routinely available on the National Health Service (NHS).
In April 2013, NHS England became responsible for its management with a single national list of drugs for prioritized funding.
As the CDF has recently been extended to 2016, it is increasingly important to understand the key criteria for inclusion on the CDF-approved list. This research aims to define those key inclusion criteria.
METHODS
CDF appraisal reports were sourced from the NHS England website1 (April 2013 -March 2014) and the date, decision, and key rationale were extracted.
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RESULTS
• 56 CDF decision summaries were available (Figure 1 • Therefore to gain the required 2 points for approval, 3 points in total are needed from the OS and PFS scores, requiring either (Table 1 ):
• 2-3 month improvement in OS AND PFS, OR
• ≥ 4 month improvement in OS OR PFS
• 11 submissions were based on only Phase II data (Figure 3) , 5 of which were approved. For such submissions, efficacy scores are halved. Magnitude of benefit PFS Score OS Score
PAREXEL International
